xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

314

KUANetal.

TABLE XXVI.2 Evidence surrounding sinonasal B-cell lymphoma (BCL) treatment.

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Eriksen et al. 1769 2022 3

1. DLBCL was the predominant subtype (80%) 2. Sinonasal BCL incidence 0.14/100,000 person-years 3. DLBCL 5-year OS 56% 4. Immunotherapy and rituximab increased OS for DLBCL patients

1. Clinicodemo graphic char acteristics 2. Treatment response 3. OS

205 patients with

Retrospective

sinonasal BCL, 163 patients with DLBCL

cohort study with pathological confirma tionof patients from Danish national cancer registry

Vahamurto et al. 1843

2019 3

Retrospective cohort

46 patients with

1. Riskof

Addition of rituximab to chemotherapy as well as

sinonasal DLBCL:

progression

21 with CHOP or CHOP-like chemotherapy 25with

2. OS

CNS-directed chemotherapy reduced the risk of progression and death and translated into betterOS 1. No significant difference in was found in the response rate or OS between groups 2. Patients with sinonasal DLBCL treated with R-CHOP have a relatively low CNS relapse rate 1. 5- and 10-year OSs were 48% and 41% 2. Intrathecal chemoprophylaxis improved OS from 20% to 51% 1. 30 out of 42 patients treated with CRT 2. 5-year OS and DFS of all patients were 57% and 59%, respectively 1. Patients treated with CRT had improved OS compared to those treated with chemotherapy alone. 2. Patients receiving immunotherapy had significantly improved OS after 2012 1. OS was 62% at 5 years and 42% at 10years 2. CRT + immunotherapy offers increased survival in patients with advanced disease (Continues) and better OS compared to previous studies with CHOP

CHOP + Rituximab

Lee et al. 1836

1. OS 2. Response rate 3. Relapse rate

2015 3

Retrospective cohort

80 patients with

primary sinonasal tract DLBCL treated with R-CHOP chemotherapy at 22 institutions in Korea

Laskin et al. 1834

2005 3

Retrospective cohort

44 patients with

1. Response rates 2. Sites of relapse 3. OS

primary paranasal sinus lymphoma

1. OS 2. DFS

Shikama

42 patients with non-Hodgkin’s

2001 3

Multicenter

et al. 1895

retrospective cohort

lymphoma of the paranasal sinuses at

25 Japanese institutions

Lehrich et al. 1764 2021

4

Retrospective database study (NCDB)

2073 patients with sinonasal DLBCL

1. OS 2. Survival by treatment modality

Brown et al. 1844

2222 patients with

1. OS 2. Survival by treatment modality

2021

4

Retrospective database study (NCDB)

sinonasal DLBCL